110 related articles for article (PubMed ID: 2627987)
1. Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies.
Gulati SC; Shimazaki C; Lemoli RM; Atzpodien J; Clarkson BD
Eur J Haematol Suppl; 1989; 51():164-72. PubMed ID: 2627987
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo treatment of myeloma cells by 4-hydroperoxycyclophosphamide and VP-16-213.
Shimazaki C; Gulati SC; Atzpodien J; Fried J; Colvin OM; Clarkson BD
Acta Haematol; 1988; 80(1):17-22. PubMed ID: 3135688
[TBL] [Abstract][Full Text] [Related]
3. In vitro cytotoxicity of VP-16-213 and nitrogen mustard: agonistic on tumor cells but not on normal human bone marrow progenitors.
Lemoli RM; Gulati SC
Exp Hematol; 1990 Oct; 18(9):1008-12. PubMed ID: 2397748
[TBL] [Abstract][Full Text] [Related]
4. Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination.
Lemoli RM; Gasparetto C; Scheinberg DA; Moore MA; Clarkson BD; Gulati SC
Blood; 1991 Apr; 77(8):1829-36. PubMed ID: 2015406
[TBL] [Abstract][Full Text] [Related]
5. Differential effect of 4-hydroperoxycyclophosphamide and antimyeloid monoclonal antibodies on T and natural killer cells during bone marrow purging.
Zhong RK; Donnenberg AD; Rubin J; Ball ED
Blood; 1994 Apr; 83(8):2345-51. PubMed ID: 7512845
[TBL] [Abstract][Full Text] [Related]
6. TGF-beta 3 protects normal human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide in vitro.
Lemoli RM; Strife A; Clarkson BD; Haley JD; Gulati SC
Exp Hematol; 1992 Dec; 20(11):1252-6. PubMed ID: 1493854
[TBL] [Abstract][Full Text] [Related]
7. Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4-hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres.
O'Briant KC; Shpall EJ; Houston LL; Peters WP; Bast RC
Cancer; 1991 Sep; 68(6):1272-8. PubMed ID: 1873781
[TBL] [Abstract][Full Text] [Related]
8. In vitro chemopurification of neuroblastoma cells: comparison of 6-hydroxydopamine and ascorbic acid with 4-hydroperoxycyclophosphamide.
Gulati SC; Kwon JH; Kushner B; Cheung NK; Atzpodien J; Shum K; Clarkson BD
Cancer Invest; 1989; 7(5):417-22. PubMed ID: 2515915
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD33 monoclonal antibody and etoposide/cytosine arabinoside combinations for the ex vivo purification of bone marrow in acute nonlymphocytic leukemia.
Stiff PJ; Schulz WC; Bishop M; Marks L
Blood; 1991 Jan; 77(2):355-62. PubMed ID: 1985700
[TBL] [Abstract][Full Text] [Related]
10. Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement.
De Fabritiis P; Bregni M; Lipton J; Greenberger J; Nadler L; Rothstein L; Korbling M; Ritz J; Bast RC
Blood; 1985 May; 65(5):1064-70. PubMed ID: 3995166
[TBL] [Abstract][Full Text] [Related]
11. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation.
LaCasse EC; Bray MR; Patterson B; Lim WM; Perampalam S; Radvanyi LG; Keating A; Stewart AK; Buckstein R; Sandhu JS; Miller N; Banerjee D; Singh D; Belch AR; Pilarski LM; Gariépy J
Blood; 1999 Oct; 94(8):2901-10. PubMed ID: 10515895
[TBL] [Abstract][Full Text] [Related]
12. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
Margolin KA; Wright C; Forman SJ
Leukemia; 1997 May; 11(5):723-8. PubMed ID: 9180298
[TBL] [Abstract][Full Text] [Related]
13. Elimination of myeloma cells from bone marrow by using monoclonal antibodies and magnetic immunobeads.
Shimazaki C; Wisniewski D; Scheinberg DA; Atzpodien J; Strife A; Gulati S; Fried J; Wisniewolski R; Wang CY; Clarkson BD
Blood; 1988 Oct; 72(4):1248-54. PubMed ID: 3167207
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis.
Chang TT; Gulati SC; Chou TC; Vega R; Gandola L; Ibrahim SM; Yopp J; Colvin M; Clarkson BD
Cancer Res; 1985 Jun; 45(6):2434-9. PubMed ID: 3857119
[TBL] [Abstract][Full Text] [Related]
15. Purging of myeloma cells from bone marrow using monoclonal antibodies and magnetic immunobeads in combination with 4-hydroperoxycyclophosphamide.
Shimazaki C; Inaba T; Murakami S; Fujita N; Nakagawa M; Gulati SC; Fried J; Clarkson BD; Wisniewolski R; Wang CY
Prog Clin Biol Res; 1990; 333():311-9. PubMed ID: 2308988
[No Abstract] [Full Text] [Related]
16. In vitro sensitivity of human hematopoietic progenitor cells to 4-hydroperoxycyclophosphamide.
Ratajczak MZ; Ratajczak J; Kuczynski W; Light B; Lusk EJ; Gewirtz AM
Exp Hematol; 1993 Dec; 21(13):1663-7. PubMed ID: 8243568
[TBL] [Abstract][Full Text] [Related]
17. Preclinical assessment of purging with VP-16-213: key role for long-term marrow cultures.
Kushner BH; Kwon JH; Gulati SC; Castro-Malaspina H
Blood; 1987 Jan; 69(1):65-71. PubMed ID: 3790729
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies.
Motta MR; Mangianti S; Rizzi S; Ratta M; Campanini E; Fortuna A; Fogli M; Tura S; Lemoli RM
Exp Hematol; 1997 Nov; 25(12):1261-9. PubMed ID: 9357970
[TBL] [Abstract][Full Text] [Related]
19. Selective depletion of human myeloma clonogenic stem cells from bone marrow cell preparations by a plasma-cell reactive antibody and complement.
Stone MJ; Tong AW; Fay JW; Lee JC
Cancer Detect Prev; 1988; 12(1-6):621-35. PubMed ID: 3180147
[TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of combination drug purging for autologous bone marrow transplantation.
Jones RJ; Miller CB; Zehnbauer BA; Rowley SD; Colvin OM; Sensenbrenner LL
Bone Marrow Transplant; 1990 May; 5(5):301-7. PubMed ID: 2350626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
